Current Opinion in Lipidology volume 25, issue 4, P289-296 2014 DOI: 10.1097/mol.0000000000000096 View full text
|
|
Share
Paul N. Durrington, Jonathan D. Schofield, Tarza Siahmansur, Handrean Soran

Abstract: We have acquired a great deal of knowledge about Lp(a), but this has not yet led to reductions in CVD. This is at least partially due to disagreement over Lp(a) measurement methodologies, its physiological role and the importance of the elevations seen in renal diseases, diabetes mellitus and familial hypercholesterolaemia. Renewed focus is required to bring assays into clinical practice to accompany new classes of therapeutic agents with Lp(a)-lowering effects.